JP2021532063A5 - - Google Patents
Info
- Publication number
- JP2021532063A5 JP2021532063A5 JP2020567044A JP2020567044A JP2021532063A5 JP 2021532063 A5 JP2021532063 A5 JP 2021532063A5 JP 2020567044 A JP2020567044 A JP 2020567044A JP 2020567044 A JP2020567044 A JP 2020567044A JP 2021532063 A5 JP2021532063 A5 JP 2021532063A5
- Authority
- JP
- Japan
- Prior art keywords
- groups
- alkyl
- antibody
- cancer
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023196433A JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 |
| JP2025165244A JP2026004432A (ja) | 2018-06-01 | 2025-10-01 | スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679672P | 2018-06-01 | 2018-06-01 | |
| US201862679631P | 2018-06-01 | 2018-06-01 | |
| US62/679,672 | 2018-06-01 | ||
| US62/679,631 | 2018-06-01 | ||
| US201862779324P | 2018-12-13 | 2018-12-13 | |
| US62/779,324 | 2018-12-13 | ||
| PCT/US2019/035015 WO2019232449A1 (en) | 2018-06-01 | 2019-05-31 | Splicing modulator antibody-drug conjugates and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023196433A Division JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532063A JP2021532063A (ja) | 2021-11-25 |
| JP2021532063A5 true JP2021532063A5 (cg-RX-API-DMAC7.html) | 2022-06-06 |
| JP7390315B2 JP7390315B2 (ja) | 2023-12-01 |
Family
ID=66999916
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567044A Active JP7390315B2 (ja) | 2018-06-01 | 2019-05-31 | スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 |
| JP2023196433A Active JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 |
| JP2025165244A Pending JP2026004432A (ja) | 2018-06-01 | 2025-10-01 | スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023196433A Active JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 |
| JP2025165244A Pending JP2026004432A (ja) | 2018-06-01 | 2025-10-01 | スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 |
Country Status (18)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL320863A (en) | 2017-10-02 | 2025-07-01 | Visterra Inc | Antibodies to CD138 and their uses |
| CN119405833A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| IL278740B2 (en) | 2018-06-01 | 2024-01-01 | Eisai R&D Man Co Ltd | Methods for using splicing modulators |
| CN111655295B (zh) | 2018-08-29 | 2024-05-28 | 荣昌生物制药(烟台)股份有限公司 | 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途 |
| CN120189526A (zh) | 2018-12-13 | 2025-06-24 | 卫材R&D管理有限公司 | 荷伯希二烯抗体-药物缀合物及使用方法 |
| US20220098578A1 (en) | 2019-01-31 | 2022-03-31 | Bar Ilan University | Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy |
| GB201905780D0 (en) * | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| BR112021025421A2 (pt) | 2019-06-17 | 2022-02-01 | Visterra Inc | Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos |
| WO2021090062A1 (en) | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
| CA3164797A1 (en) * | 2019-12-23 | 2021-07-01 | Eisai R&D Management Co., Ltd. | Method of producing eribulin based antibody-drug conjugate |
| US20230338564A1 (en) * | 2020-03-31 | 2023-10-26 | Orum Therapeutics, Inc. | Neodegrader conjugates |
| WO2021247769A1 (en) | 2020-06-02 | 2021-12-09 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
| EP4161966A1 (en) * | 2020-06-05 | 2023-04-12 | Eisai R&D Management Co., Ltd. | Anti-bcma antibody-drug conjugates and methods of use |
| US20240043928A1 (en) | 2020-11-04 | 2024-02-08 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| TW202306588A (zh) * | 2021-05-21 | 2023-02-16 | 中國大陸商榮昌生物製藥(煙臺)股份有限公司 | 抗體-藥物結合物與免疫檢查點抑制劑組合用於治療泌尿上皮癌之用途 |
| US20230348614A1 (en) * | 2021-11-24 | 2023-11-02 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| CN114573698B (zh) * | 2022-03-16 | 2023-01-06 | 沈阳三生制药有限责任公司 | 一种FcRn抗原结合蛋白及其制备方法和应用 |
| CN115974976B (zh) * | 2022-11-23 | 2024-06-04 | 华中科技大学 | 拮抗多肽及用于制备抗急性肾损伤药物的应用 |
| LT4601703T (lt) | 2023-04-18 | 2026-06-25 | Astrazeneca Ab | Konjugatai, apimantys atskeliamuosius jungtukus |
| IL327670A (en) | 2023-10-11 | 2026-06-01 | Antikor Biopharma Ltd | Antibodies, conjugates, and uses thereof |
| CN122497691A (zh) * | 2023-12-19 | 2026-07-31 | 百欧恩泰欧洲股份公司 | Cfc1结合分子 |
| AU2024404304A1 (en) * | 2023-12-19 | 2026-05-21 | BioNTech SE | Cfc1 binding molecule |
| WO2025240362A1 (en) * | 2024-05-13 | 2025-11-20 | The Board Of Trustees Of The Leland Stanford Junior University | Discovery of enpp3 as a cgamp hydrolase with a role in anti-cancer immunity |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| NZ322175A (en) | 1995-11-10 | 1999-02-25 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying the same |
| EP0871490B1 (en) | 1995-12-22 | 2003-03-19 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
| US5985320A (en) | 1996-03-04 | 1999-11-16 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| ES2198922T3 (es) | 1998-06-24 | 2004-02-01 | Advanced Inhalation Research, Inc. | Particulas porosas grandes emitadas por un inhalador. |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US7555503B1 (en) | 2000-06-30 | 2009-06-30 | Click Commerce, Inc. | Method and apparatus for managing updates to a catalog |
| TWI312681B (en) | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| CZ20033208A3 (en) | 2001-04-26 | 2004-03-17 | Biogen, Inc. | Cripto blocking antibodies and uses thereof |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| RU2338741C2 (ru) | 2002-07-31 | 2008-11-20 | Мершан Корпорейшн | Новые физиологически активные вещества |
| US7576204B2 (en) | 2002-07-31 | 2009-08-18 | Mercian Corporation | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| ATE469985T1 (de) | 2004-02-06 | 2010-06-15 | Eisai R&D Man Co Ltd | Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel |
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| JP4993645B2 (ja) | 2004-12-01 | 2012-08-08 | ジェネンテック, インコーポレイテッド | 抗体薬剤結合体および方法 |
| KR20080080482A (ko) | 2005-09-07 | 2008-09-04 | 메디뮨 엘엘씨 | 독소가 컨쥬게이트된 eph 수용체 항체 |
| CN101282967B (zh) | 2005-10-13 | 2011-01-26 | 卫材R&D管理有限公司 | 普拉二烯内酯b和普拉二烯内酯d的全合成 |
| WO2008016187A1 (en) | 2006-08-02 | 2008-02-07 | Eisai R & D Management Co., Ltd. | Pladienolide target molecule, compound capable of binding to the target molecule, and screening method for the compound |
| PT2845866T (pt) | 2006-10-27 | 2017-08-09 | Genentech Inc | Anticorpos e imunoconjugados e utilizações dos mesmos |
| US7790887B2 (en) | 2007-01-29 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same |
| WO2008111464A1 (ja) | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
| WO2009008492A1 (ja) | 2007-07-06 | 2009-01-15 | Eisai R & D Management Co., Ltd. | マクロライド系化合物の製造方法およびその製造中間体 |
| US8653283B2 (en) | 2009-04-17 | 2014-02-18 | The Regents Of The University Of California | Anticancer agents |
| JPWO2011074621A1 (ja) | 2009-12-18 | 2013-04-25 | 株式会社医学生物学研究所 | メソセリン(msln)に対する抗体及びその用途 |
| KR20150006000A (ko) | 2012-05-01 | 2015-01-15 | 제넨테크, 인크. | 항-pmel17 항체 및 면역접합체 |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物,偶联方法,及其用途 |
| US20140069822A1 (en) | 2012-09-10 | 2014-03-13 | Antec Leyden B.V. | Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction |
| US9155357B2 (en) | 2012-09-11 | 2015-10-13 | Nike, Inc. | Automated strobel printing |
| MX340090B (es) * | 2012-11-05 | 2016-06-23 | Pfizer | Analogos de spliceostatina. |
| US20140275010A1 (en) * | 2013-03-12 | 2014-09-18 | Guo Zhu Zheng | Quaternary salts |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| KR20160042871A (ko) | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | 폴리펩티드의 효소적 콘쥬게이션 |
| US10195289B2 (en) | 2013-07-31 | 2019-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
| MX371455B (es) | 2013-08-02 | 2020-01-28 | Pfizer | Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco. |
| EP3066470A4 (en) | 2013-11-05 | 2017-05-31 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| KR20190072663A (ko) | 2014-04-25 | 2019-06-25 | 리나트 뉴로사이언스 코프. | 약물이 고도로 로딩된 항체-약물 접합체 |
| RS58400B1 (sr) | 2014-05-15 | 2019-04-30 | Eisai R&D Man Co Ltd | Jedinjenja pladienolid piridina i postupci primene |
| JP6349171B2 (ja) | 2014-07-07 | 2018-06-27 | ローム株式会社 | ノイズ除去回路、タイミングコントローラ、ディスプレイ装置、電子機器、ソースドライバの制御方法 |
| CN106604933B (zh) | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| HUE049325T2 (hu) | 2014-08-28 | 2020-09-28 | Pfizer | Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra |
| AU2016206475B2 (en) | 2015-01-16 | 2021-11-04 | City Of Hope | Cell penetrating antibodies |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| WO2017011803A1 (en) * | 2015-07-16 | 2017-01-19 | Cellerant Therapeutics, Inc. | Cysteine-substituted immunoglobulins |
| EP3344780B1 (en) | 2015-09-01 | 2021-06-23 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
| IL259198B2 (en) | 2015-11-18 | 2023-04-01 | Eisai R&D Man Co Ltd | A solid form of paladinolide pyridine compound and methods of its use |
| US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| ES2904593T3 (es) | 2016-01-21 | 2022-04-05 | Pfizer | Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos |
| MY199595A (en) | 2016-03-02 | 2023-11-08 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| CN105669800B (zh) | 2016-03-03 | 2017-12-15 | 湖南省农产品加工研究所 | 一种从柑橘中联合提取精油、果胶、橙皮苷、辛弗林和柠檬苦素的方法 |
| CN117534764A (zh) | 2016-06-06 | 2024-02-09 | 阿布泽纳(英国)有限公司 | 抗体、其用途及其缀合物 |
| KR20220147719A (ko) | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| CN111801353B (zh) | 2017-10-13 | 2024-09-17 | A&G药品公司 | 针对前列腺素f2受体抑制剂的单克隆抗体和缀合物及其用途 |
| CA3096400A1 (en) | 2018-04-09 | 2019-10-17 | Eisai R&D Management Co., Ltd. | Certain pladienolide compounds and methods of use |
| CA3096424A1 (en) | 2018-04-12 | 2019-10-17 | Eisai R&D Management Co., Ltd. | Pladienolide derivatives as spliceosome targeting agents for treating cancer |
| IL278740B2 (en) | 2018-06-01 | 2024-01-01 | Eisai R&D Man Co Ltd | Methods for using splicing modulators |
| CN119405833A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| CN120189526A (zh) | 2018-12-13 | 2025-06-24 | 卫材R&D管理有限公司 | 荷伯希二烯抗体-药物缀合物及使用方法 |
| WO2021090062A1 (en) | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
| JP7821733B2 (ja) | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| EP4161966A1 (en) | 2020-06-05 | 2023-04-12 | Eisai R&D Management Co., Ltd. | Anti-bcma antibody-drug conjugates and methods of use |
-
2019
- 2019-05-31 CN CN202411513264.7A patent/CN119405833A/zh active Pending
- 2019-05-31 KR KR1020207035785A patent/KR20210016375A/ko active Pending
- 2019-05-31 WO PCT/US2019/035015 patent/WO2019232449A1/en not_active Ceased
- 2019-05-31 PE PE2020001954A patent/PE20211220A1/es unknown
- 2019-05-31 JP JP2020567044A patent/JP7390315B2/ja active Active
- 2019-05-31 CN CN202411513167.8A patent/CN119405831A/zh active Pending
- 2019-05-31 CN CN202411513294.8A patent/CN119405834A/zh active Pending
- 2019-05-31 SG SG11202010341PA patent/SG11202010341PA/en unknown
- 2019-05-31 BR BR112020024549-6A patent/BR112020024549A2/pt unknown
- 2019-05-31 MX MX2020012997A patent/MX2020012997A/es unknown
- 2019-05-31 IL IL305431A patent/IL305431B2/en unknown
- 2019-05-31 IL IL279062A patent/IL279062B2/en unknown
- 2019-05-31 CN CN201980036786.3A patent/CN112218663B/zh active Active
- 2019-05-31 AU AU2019277700A patent/AU2019277700C1/en active Active
- 2019-05-31 US US17/059,635 patent/US12172986B2/en active Active
- 2019-05-31 IL IL316090A patent/IL316090A/en unknown
- 2019-05-31 JO JOP/2020/0268A patent/JOP20200268A1/ar unknown
- 2019-05-31 CN CN202411513187.5A patent/CN119405832A/zh active Pending
- 2019-05-31 TW TW114103019A patent/TW202519520A/zh unknown
- 2019-05-31 CA CA3099920A patent/CA3099920A1/en active Pending
- 2019-05-31 EP EP19732510.3A patent/EP3801632A1/en active Pending
-
2020
- 2020-11-26 PH PH12020500672A patent/PH12020500672A1/en unknown
- 2020-11-30 CL CL2020003117A patent/CL2020003117A1/es unknown
- 2020-11-30 US US17/247,117 patent/US11352348B2/en active Active
- 2020-12-22 CO CONC2020/0016137A patent/CO2020016137A2/es unknown
-
2021
- 2021-09-10 CL CL2021002378A patent/CL2021002378A1/es unknown
- 2021-09-10 CL CL2021002377A patent/CL2021002377A1/es unknown
-
2022
- 2022-05-03 US US17/661,909 patent/US11945807B2/en active Active
-
2023
- 2023-05-31 JO JOJO/P/2023/0123A patent/JOP20230123A1/ar unknown
- 2023-05-31 JO JOJO/P/2023/0124A patent/JOP20230124A1/ar unknown
- 2023-11-20 JP JP2023196433A patent/JP7753317B2/ja active Active
-
2024
- 2024-02-19 US US18/581,307 patent/US12514926B2/en active Active
- 2024-04-19 CL CL2024001240A patent/CL2024001240A1/es unknown
- 2024-04-19 CL CL2024001239A patent/CL2024001239A1/es unknown
- 2024-04-19 CL CL2024001242A patent/CL2024001242A1/es unknown
- 2024-04-19 CL CL2024001241A patent/CL2024001241A1/es unknown
- 2024-04-19 CL CL2024001243A patent/CL2024001243A1/es unknown
- 2024-09-10 US US18/830,446 patent/US20250135017A1/en active Pending
-
2025
- 2025-10-01 JP JP2025165244A patent/JP2026004432A/ja active Pending
- 2025-11-11 US US19/385,593 patent/US20260158152A1/en active Pending
-
2026
- 2026-04-21 AU AU2026202985A patent/AU2026202985A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512401A5 (cg-RX-API-DMAC7.html) | ||
| JP5925684B2 (ja) | 抗gcc分子と関連組成物および方法 | |
| CN108026123B (zh) | 用于偶联的亲水链接体 | |
| ES2874306T3 (es) | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 | |
| KR102023496B1 (ko) | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 | |
| US7067131B2 (en) | Methods for using anti-MUC18 antibodies | |
| ES2818575T3 (es) | Reducción selectiva de anticuerpos con modificación de cisteínas | |
| ES2795818T3 (es) | Anticuerpos CD48 y conjugados de los mismos | |
| CN106414465B (zh) | 带电荷链接体及其在共轭反应上的应用 | |
| RU2018134331A (ru) | Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения | |
| JP2023500875A5 (cg-RX-API-DMAC7.html) | ||
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| JP7570329B2 (ja) | ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 | |
| JP7827624B2 (ja) | 抗cea抗体-エキサテカン類似体複合体及びその医薬用途 | |
| EP3600444A1 (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
| RU2014148162A (ru) | Анти-pmel17 антитела и их иммуноконъюгаты | |
| TW201905000A (zh) | 含有抗globo h抗體之抗體-藥物共軛物及其用途 | |
| CN113453724B (zh) | 基于磺酰基马来酰亚胺的连接子和相应的偶联物 | |
| JPWO2023033129A5 (cg-RX-API-DMAC7.html) | ||
| US20260021194A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| JP2016511257A (ja) | 癌の治療における抗gcc抗体−薬物複合体及びdna損傷剤の投与 | |
| NZ771328B2 (en) | Splicing modulator antibody-drug conjugates and methods of use | |
| RU2024115226A (ru) | Конъюгаты антитела и лекарственного средства, содержащие модулятор сплайсинга на основе гербоксидиена, и способы их применения | |
| NZ771328A (en) | Splicing modulator antibody-drug conjugates and methods of use | |
| US20260061066A1 (en) | Anti-grp78 antibody, immunoconjugate and uses thereof |